David D. Frisbie
Veterinary at Garfield St, Fort Collins, CO
License number
Colorado 6033
Issued Date
Nov 11, 1994
Renew Date
Nov 1, 2016
Expiration Date
Oct 31, 2018
Type
Veterinarian
Address
Address
708 Garfield St, Fort Collins, CO 80524
Professional information
In Vivo Treatment Of Joint Disease Using Interleukin-1
US Patent:
2003009, May 15, 2003
Filed:
Mar 7, 2002
Appl. No.:
10/092849
Inventors:
David Frisbie - Fort Collins CO, US
C. McIlwraith - Fort Collins CO, US
C. McIlwraith - Fort Collins CO, US
Assignee:
Colorado State University Research Foundation
International Classification:
A61K048/00, C12N015/86, A61K038/20
US Classification:
424/093200, 424/085200, 514/044000, 435/456000
Abstract:
Adenovirus particles encoding an interleukin-1 receptor antagonist were found to be effective in treating joint disease over an extended period of time when administered directly via arthrocentesis. Administration of the adenovirus particles resulted in an increase in interleukin-1 receptor antagonist protein concentration, increased influx of white blood cells, increased percentage of neutrophils, and a lower percentage of mononuclear cells when compared to control experiments.
Agents And Methods For Diagnosing Osteoarthritis
US Patent:
2009022, Sep 10, 2009
Filed:
Jul 22, 2005
Appl. No.:
11/571981
Inventors:
Richard Bruce Brandon - Queensland, AU
Mervyn Rees Thomas - Queensland, AU
David D. Frisbie - Fort Collins CO, US
C. Wayne McIlwraith - Loveland CO, US
Mervyn Rees Thomas - Queensland, AU
David D. Frisbie - Fort Collins CO, US
C. Wayne McIlwraith - Loveland CO, US
Assignee:
Colorado State University Research Foundation - Fort Collins CO
International Classification:
C12Q 1/68, G01N 33/53, C40B 30/04, A61K 36/87, C07H 21/00, C12N 15/63, C12N 5/10, C12N 1/00, C07K 2/00, A61P 13/00
US Classification:
424766, 435 6, 435 78, 506 9, 536 231, 4353201, 435325, 536 2431, 530402, 435243
Abstract:
This present invention discloses disease-associated molecules and assays, which are useful for diagnosing the presence or risk of developing osteoarthritis (OA) or related conditions. The invention has practical use in the early diagnosis of disease, in monitoring mammals at risk of developing OA, and in enabling better treatment and management decisions to be made in clinically and sub-clinically affected animals.